Something posted elsewhere: https://www-nytimes
Post# of 36514
![](/assets/46931549/no_avatar_available_thumb.jpg)
https://www-nytimes-com.cdn.ampproject.org/c/...e207B7z-_M
Comment by Joe: An important development for COVID-19 vaccine developers - identifying IGg antibody endpoints for effectiveness measures enables the development of second generation vaccines that are new and improved over the current genetic vaccines without having to conduct trials with 50,000 people. Good stuff
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)